Comparison of Commission on Cancer–Approved and –Nonapproved Hospitals in the ... previous antiangiogenic therapies/VEGFR-2 inhibitors. Written informed consent from all patients and approval from the ...

We used the SEER cancer registry linked to 2007 to 2016 Medicare claims ... CML, chronic myelogenous leukemia; PHC, Personal Health Care; TKI, tyrosine kinase inhibitor; USD, US dollars. Overall, the ...

PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the ...

Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM TOKYO, /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development ...

Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, the "Company") will present results from six ...

Earlier this year, Cullinan said its lead candidate hit the bull's-eye in a midstage lung cancer cancer trial but stayed mum on the details. Now, the biotech is revealing the results that have ...

Asandeutertinib is a derivative of Tagrisso designed to avoid certain toxic side effects in patients with EGFR-mutated NSCLC.

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved ...

SU11657 (SUGEN) is a selective multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity exerted by targeting PDGF receptors (PDGFR), VEGF receptors (VEGFR), stem cell ...

Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate. However, primary and secondary resistance have ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...